Medicine & Life Sciences
Breast Neoplasms
100%
Drug Therapy
27%
Cancer Survivors
26%
Neoplasms
21%
Triple Negative Breast Neoplasms
20%
Aurora Kinase A
18%
Hormones
18%
Physiologic Monitoring
17%
palbociclib
15%
Therapeutics
13%
human ERBB2 protein
13%
Fulvestrant
13%
Trastuzumab
13%
Anastrozole
13%
Somatomedins
12%
Survivors
12%
Survivorship
11%
MLN 8237
11%
exemestane
11%
Telemedicine
11%
Paclitaxel
11%
Estrogen Receptors
9%
Pandemics
8%
Biomarkers
8%
Doxorubicin
8%
Residual Neoplasm
7%
Anthracyclines
7%
Random Allocation
7%
sapanisertib
7%
Clinical Trials
6%
Estrogens
6%
Adjuvant Chemotherapy
6%
Cyclophosphamide
6%
Lapatinib
6%
Neoadjuvant Therapy
6%
dalotuzumab
6%
Quality of Life
6%
anti-IGF-1R antibody A12
5%
Aromatase Inhibitors
5%
trebananib
5%
Heart Failure
5%
Progression-Free Survival
5%
Patient Satisfaction
5%
Disease-Free Survival
5%
ridaforolimus
5%
Hospitalization
5%
Breast
5%
Cilengitide
5%
Technology
5%
N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide
5%